Breast Cancer Response Evaluation for Individualized Therapy
common.study.values.description
“RNA Disruption Assay (RDA)-Breast Cancer Response Evaluation for Individualized Therapy BREVITY”
The current study (BREVITY) aims to provide validation results of RNA Disruption Assay (RDA) as a tumour response assessment tool that uses tumour core biopsies at ~2-3 weeks after the initiation of neoadjuvant chemotherapy.
common.study.values.location
participant.ui.study.affiliations-map.online-study.header-virtual
participant.ui.study.affiliations-map.online-study.text
common.study.values.methods
common.study.methods.has-drugs-no
common.study.methods.is-healthy-yes
Procedure - Core needle biopsy
1st core needle biopsy for RDA 2 specimens: Time Point: ~2-3 weeks after initiation of 1st cycle of chemotherapy; Timing by type of drug schedule 3-weekly: at 16 days +/- 2 days, Bi-weekly: at day of 2nd dose preferably before drug admin., Weekly: at day of 4th dose preferably before drug admin. 2nd core needle biopsy for RDA: Time Point: if therapy is changed (as part of SoC), a second biopsy ~2-3 weeks after initiation of new drugs; Timing by type of drug schedule 3-weekly: at 16 days +/- 2 da ...read more on ClinicalTrials.org
participant.views.study.view.additional
participant.views.study.view.scientific-title
RNA Disruption Assay (RDA)-Breast Cancer Response Evaluation for Individualized Therapy (BREVITY)
common.study.values.clinical-trial-id
NCT03524430
participant.views.study.view.id
wdLNDa
